REG - Surgical Innovations - Withdrawal of AGM Resolutions 9 and 10

Surgical InnovationsAnnouncement

26/06/2025 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nRSZ5787Oa&default-theme=true

RNS Number : 5787O  Surgical Innovations Group PLC  26 June 2025

Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

 
Withdrawal of AGM Resolutions 9 and 10

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and
distributor of innovative medical technology for minimally invasive surgery
("MIS"), advises that the Board has withdrawn Resolutions 9 and 10 from the
agenda of the Annual General Meeting ("AGM") of the Company's shareholders
scheduled to be held at 11:00 a.m. tomorrow, 27 June 2025, at the offices of
Singer Capital Markets at 1 Bartholomew Lane, London, EC2N 2AX.

 

Resolutions 9 and 10 were special resolutions relating to the disapplication
of pre-emption rights in respect of the allotment of equity securities for
cash with limits in line with the Pre-Emption Group's 2022 Statement of
Principles.  Whilst the Board considers the flexibility afforded by these
authorities to be in the best interests of the Company, it has taken the
decision to withdraw Resolutions 9 and 10 from the agenda of the AGM following
feedback received from a small number of significant shareholders in the
Company since the publication of the notice of the AGM.

 

The withdrawal of Resolutions 9 and 10 does not affect the validity of the
notice of the AGM, the proxy form or any votes submitted in respect of the
remaining resolutions to be proposed at the AGM.  Arrangements for the AGM
are unchanged from those previously notified as is the numbering of all other
proposed resolutions at the AGM.

 

The withdrawal of Resolutions 9 and 10 does not affect the strategy or the
day-to-day running of the business and the Directors do not currently envisage
that the business would need to raise new funds through the issue of new
shares on a non pre-emptive basis before the 2026 AGM. Should such need arise,
a separate General Meeting would be convened to seek shareholder approval at
the relevant time.

 

 

 

For further information please contact:

 

 Surgical Innovations Group plc                                                www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                                              Tel: 0113 230 7597
 Brent Greetham, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                                                     Tel: 020 7496 3000
 Alex Bond / Oliver Platts

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Lianne Applegarth                                              Mob: 07980 541 893 / 07584 391 303

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist
products employed in laparoscopy, bariatric and metabolic surgery, hernia
repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM
partners and have also collaborated with a major UK industrial partner to
provide precision engineering solutions to complex problems outside the
medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a broad portfolio of cost
effective, procedure specific surgical instruments and implantable devices
that offer reliable solutions to genuine clinical needs, the Company's
Reposable portfolio enables healthcare providers to reduce both plastic waste
and their CO2 footprint as they strive for net zero.

 

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

 

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com/)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUWWQUPAGUQ